venBio Select Advisor LLC purchased $15.5M worth of shares in Mirati Therapeutics, Inc. in June 2018

Jul 08, 2018
Insider Transactions
Background Information
AVCAP aims to achieve attractive returns with moderate risk. The firm invests primarily in the equity, debt and associated derivatives of companies operating in the life sciences sector and related industries with a focus on publicly traded, and late-stage private biotechnology companies.
Mirati Therapeutics, Inc. is a clinical-stage oncology company. The firm engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.